ID   Ba/F3 EGFR-D770_N771insSVD [Taiho Pharmaceutical]
AC   CVCL_E6DI
RX   PubMed=29748209;
RX   PubMed=31467113;
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:3236; EGFR (Note=With p.Asp770_Asn771insSerValAsp (c.2311_2312insGCGTGGACA)).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: Pro-B cell; CL=CL_0000826.
CC   Breed/subspecies: C3H.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_0161 ! Ba/F3
CA   Factor-dependent cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=29748209; DOI=10.1158/1535-7163.MCT-17-1206;
RA   Hasako S., Terasaka M., Abe N., Uno T., Ohsawa H., Hashimoto A.,
RA   Fujita R., Tanaka K., Okayama T., Wadhwa R., Miyadera K., Aoyagi Y.,
RA   Yonekura K., Matsuo K.;
RT   "TAS6417, a novel EGFR inhibitor targeting exon 20 insertion
RT   mutations.";
RL   Mol. Cancer Ther. 17:1648-1658(2018).
//
RX   PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223;
RA   Udagawa H., Hasako S., Ohashi A., Fujioka R., Hakozaki Y., Shibuya M.,
RA   Abe N., Komori T., Haruma T., Terasaka M., Fujita R., Hashimoto A.,
RA   Funabashi K., Yasuda H., Miyadera K., Goto K., Costa D.B.,
RA   Kobayashi S.S.;
RT   "TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase
RT   inhibitor with a broad spectrum of preclinical activity against
RT   clinically relevant EGFR mutations.";
RL   Mol. Cancer Res. 17:2233-2243(2019).
//